<DOC>
	<DOCNO>NCT02547493</DOCNO>
	<brief_summary>Is pneumococcal conjugate vaccine ( induce T-dependent humoral response ) efficient pneumococcal polysaccharide vaccine ( induce T-independent humoral response ) RA patient treat abatacept , biotherapy target T-cells ? The investigator propose conduct prospective , multicenter ( 11 center ) , randomize , open-label study . The patient go randomized 2 group : patient first group vaccinate polysaccharide pneumococcal vaccine ( Pneumo23® ) whereas patient second group vaccinate conjugate pneumococcal vaccine ( Prevenar13® ) .</brief_summary>
	<brief_title>Vaccination Against Pneumococcal Naïve Abatacept Rheumatoid Arthritis Patients</brief_title>
	<detailed_description>The study population RA patient 18 85 year instauration treatment sub-cutaneous abatacept association methotrexate agree participate study . At time inclusion , patient randomize receive either pneumococcal polysaccharide vaccine ( PPSV ) pneumococcal conjugate vaccine ( PCV ) . The primary endpoint evaluate one month vaccination . The total follow-up 12 month . For patient group PCV , prime-boost strategy apply order accordance current French recommendation revaccination 2 month initial vaccine realize PPSV .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>RA accord American College Rheumatology ( ACR ) /European League Against rheumatism ( EULAR ) 2010 criteria Disease Activity Score ( DAS ) 28 ≥ 3.2 Initiation treatment subcutaneous abatacept combination methotrexate ( MTX ) , whatever treatment receiving ( apart rituximab ( RTX ) last year ) Patient sign study consent form age &lt; 18 &gt; 85 year dementia patient subject legal protection measure Corticosteroids ≥ 10mg/d day inclusion Patient pneumococcal vaccination previous 3 year Last pneumococcal vaccination &lt; 3 year rituximab last year History anaphylactic response vaccination Contraindications abatacept methotrexate Pregnancy pregnancy wish Breast feeding Patient currently abuse drug alcohol Subject receive live vaccine within 3 month anticipate first dose study medication . Subject receive vaccine within 1 month anticipate first dose study medication duration study Patient contraindication intramuscular injection Subject respiratory insufficiency Subject risk Tuberculosis . Blood transfusion within 3 month previous study duration study . Concomitant biologic diseasemodifying antirheumatic drug ( DMARD ) Within 4 week receive treatment investigational drug . Patient positive hepatitis B surface antigen Patient positive hepatitis C antibody presence hepatitis C virus also show polymerase chain reaction recombinant immunoblot assay .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Vaccination Pneumococcal</keyword>
	<keyword>Naïve Abatacept patient</keyword>
</DOC>